Micrologix Licenses Anti-Infective to Fujisawa
By Business Review Editor
Pharma Deals Review: Vol 2002 Issue 26 (Table of Contents)
Published: 2 Jul-2002
DOI: 10.3833/pdr.v2002.i26.1032 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Micrologix Biotech and Fujisawa Healthcare entered into a collaboration and licensing agreement to co-develop and commercialize Micrologix’s proprietary cationic peptide product candidate, MBI 226 useful for preventing CVC-related blood stream infections...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS